Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 266.96M | $ 257.24M | $ 211.04M | $ 326.55M | $ 475.82M |
| Gross Profit | $ 149.41M | $ 94.46M | $ 140.96M | $ 268.96M | $ 438.16M |
| Operating Income | $ -111.67M | $ -203.20M | $ -256.88M | $ -263.86M | $ 156.32M |
| EBITDA | $ 60.94M | $ -193.94M | $ -255.58M | $ -260.69M | $ 161.84M |
| Net Income | $ 28.51M | $ -237.89M | $ -326.63M | $ -306.32M | $ 132.24M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 125.99M | $ 117.75M | $ 191.68M | $ 417.19M | $ 541.16M |
| Total Assets | $ 448.53M | $ 629.60M | $ 480.85M | $ 679.33M | $ 841.65M |
| Total Debt | $ 269.90M | $ 480.84M | $ 471.06M | $ 408.28M | $ 404.02M |
| Net Debt | $ 143.92M | $ 377.95M | $ 407.51M | $ -8.91M | $ -137.13M |
| Total Liabilities | $ 580.52M | $ 823.03M | $ 618.26M | $ 581.61M | $ 560.67M |
| Stockholders' Equity | $ -131.99M | $ -193.43M | $ -137.42M | $ 97.73M | $ 280.97M |
| Cash Flow | |||||
| Free Cash Flow | $ -20.44M | $ -175.17M | $ -243.16M | $ -38.72M | $ 147.09M |
| Operating Cash Flow | $ -20.44M | $ -174.88M | $ -241.12M | $ -37.43M | $ 154.15M |
| Investing Cash Flow | $ 230.32M | $ 144.64M | $ -166.85M | $ -138.41M | $ -14.40M |
| Financing Cash Flow | $ -186.97M | $ 69.60M | $ 54.33M | $ 51.88M | $ 223.95M |